Free Trial

Athersys (ATHX) Competitors

Athersys logo

ATHX vs. SPRB, AFMD, OGEN, PTN, GRAY, GRTX, VCNX, ONCT, ADXS, and BPTH

Should you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Spruce Biosciences (SPRB), Affimed (AFMD), Oragenics (OGEN), Palatin Technologies (PTN), Graybug Vision (GRAY), Galera Therapeutics (GRTX), Vaccinex (VCNX), Oncternal Therapeutics (ONCT), Ayala Pharmaceuticals (ADXS), and Bio-Path (BPTH).

Athersys vs. Its Competitors

Spruce Biosciences (NASDAQ:SPRB) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

In the previous week, Spruce Biosciences and Spruce Biosciences both had 1 articles in the media. Athersys' average media sentiment score of 0.75 beat Spruce Biosciences' score of 0.00 indicating that Athersys is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spruce Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Athersys
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Athersys has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Athersys' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Spruce Biosciences-555.23% -62.10% -47.49%
Athersys N/A N/A -223.03%

Spruce Biosciences has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500.

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Spruce Biosciences has higher revenue and earnings than Athersys. Spruce Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce Biosciences$4.91M0.63-$47.92M-$1.32-0.06
Athersys$146K0.00-$72.53M-$2.03N/A

Spruce Biosciences presently has a consensus target price of $1.75, suggesting a potential upside of 2,307.15%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Spruce Biosciences is more favorable than Athersys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spruce Biosciences
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Athersys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Spruce Biosciences beats Athersys on 9 of the 13 factors compared between the two stocks.

Get Athersys News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATHX vs. The Competition

MetricAthersysPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$833K$789.32M$5.51B$8.95B
Dividend YieldN/A4.84%5.25%4.04%
P/E Ratio0.001.3028.0220.16
Price / SalesN/A227.08405.99173.08
Price / CashN/A23.4437.0657.97
Price / BookN/A6.138.125.62
Net Income-$72.53M-$27.58M$3.16B$248.50M

Athersys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATHX
Athersys
N/AN/AN/AN/A$833K$146K0.0024News Coverage
SPRB
Spruce Biosciences
2.1887 of 5 stars
$0.07
+0.7%
$1.75
+2,313.8%
-87.1%$3.06M$4.91M-0.0820Gap Down
AFMD
Affimed
2.9277 of 5 stars
$0.18
-34.9%
$3.62
+1,895.9%
-96.4%$2.92M$877K0.00200Gap Down
High Trading Volume
OGEN
Oragenics
0.0706 of 5 stars
$3.82
-5.7%
N/A-95.5%$2.73M$40K-0.545Gap Down
PTN
Palatin Technologies
N/A$0.09
-44.6%
N/AN/A$2.45M$350K-0.0630Gap Down
High Trading Volume
GRAY
Graybug Vision
N/A$1.43
flat
N/A-64.2%$2.25MN/A-0.8327Gap Up
High Trading Volume
GRTX
Galera Therapeutics
0.2818 of 5 stars
$0.03
-4.6%
N/A-79.7%$2.15MN/A-0.0830Gap Down
VCNX
Vaccinex
0.4161 of 5 stars
$0.73
flat
N/A-87.0%$1.90M$388K-0.0240Gap Up
ONCT
Oncternal Therapeutics
N/A$0.53
flat
$10.00
+1,799.0%
N/A$1.56M$790K-0.0530
ADXS
Ayala Pharmaceuticals
N/A$0.03
+22.9%
N/A-19.8%$1.42M$3.24M0.0020
BPTH
Bio-Path
0.7328 of 5 stars
$0.17
-3.4%
$20.00
+11,664.7%
-89.9%$1.41MN/A0.0010

Related Companies and Tools


This page (NASDAQ:ATHX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners